However, due to the continued use of afatinib in EGFR mutation–positive patients with advanced NSCLC, the advanced practitioner will need to be properly trained to educate, prescribe, and monitor patients receiving it. This evidence concerns the gene EGFR and non-small cell lung carcinoma.